Reference

The effect of allylestrenol on human chorionic somatomammotropin synthesis of the placenta during normal pregnancy

The effect of allylestrenol on human chorionic somatomammotropin synthesis of the placenta during normal pregnancy. Gati, I.; Doszpod, J.; Hadnagy, J.; Preisz, J.; Szigetvari, I.; Rakoczi, I. (Dep. Obstet. Gynaecol., Univ. Med. Sch., Pecs, Hung.). Acta Paediatr. Acad. Sci. Hung., 17(4), 263-6 (English) 1976. CODEN: APHNAB. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) After the administration of allylestrenol (I) [432-60-0] (10 mg 3 times daily for 12 days) to healthy pregnant women in the 5th-8th month of pregnancy, the serum chorionic somatomammotropin [9035-54-5] level was increased. Apparently, I can increase chorionic somatomammotropin biosynthesis by the syncytiotrophoblasts within 12 days.

Baldness treatment with progestogens

Baldness treatment with progestogens. Mortimer, Christopher H. (UK ). Belg. BE 898057 A1 15 Feb 1984,21 pp. (French). (Belgium). CODEN: BEXXAL. ICI: A61; C07. APPLICATION: BE 21-754 21 Oct 1983. PRIORITY: US 82-435798 21 Oct 1982. DOCUMENT TYPE: Patent CA Section: 2 (Mammalian Hormones) Section cross-reference(s): 63 Baldness is treated with hormones, which show a max. progestogen activity and a min. androgen activity such as medroxyprogesterone acetate (I) [71-58-9], allylestrenol [432-60-0], norgestrel [6533-00-2], etc. These compds. decrease the content of dihydrotestosterone (II) [521-18-6] in plasma, while preserving the normal testosterone (III) [58-22-0] levels, thus preserving the sexual potency. The hormones may be administered in a variety of pharmaceutical formulations. Thus, a male patient with baldness was treated orally with I. After 1 wk of treatment the level of III decreased from 28.1 nmol/L to 14. 521-18-6 and 58-22-0 are also in the experiment.5 nmol/L and that of II decreased from 3.5 nmol/L to 1.96 nmol/L. During the 41 wk treatment, the III level in plasma varied from 8.2-15.0 nmol/L and the II level from 0.21-2.21 nmol/L. The patient did not experience any loss in sexual potency. .